Biotech Values

[oc631]

ABBV/ENTA—Do you concur with the SAPHIRE-1/2 expectations in #msg-92714916?

Your target numbers are in-line with my own expectations. Treatment-experienced patients in SAPHIRE-2 (SVR12>=90%) may be the tougher nut to crack. A couple of questions



1- Has ABBV disclosed the GT1A to GT1B patient ratio in SAPHIRE-1/2?

2- Are any of the treatment-experienced patients in SAPHIRE-2 P.I. failures?


The PEARL studies (without ribavirin) will be more difficult to call, and of greater future importance IMO.